Fig. 1

ALKBH5 is required for cell growth of t (8;21) AML. A Comparison of the mRNA levels of ALKBH5 in normal BMMNCs (n = 3) and t (8;21) AML patient BMMNCs (n = 12). B Comparison of the protein levels of ALKBH5 between normal and AML patients. C Western blot of ALKBH5 protein between normal MNCs and Kasumi-1 cells. D Kaplan–Meier curve analysis between high-ALKBH5 and low-ALKBH5 groups in TCGA-LAML cohort. The median of ALKBH5 expression was used as a cut-off value. The mRNA (E) and protein (F) level of ALKBH5 upon treatment with shNC, shALKBH5#1, or shALKBH5#2 in Kasumi-1 cells. Effects of ALKBH5 knockdown on colony-formation (G) cell growth/proliferation (H), and apoptosis (I) of Kasumi-1 cells. Effects of ALKBH5 knockdown on cell growth/proliferation (J), and apoptosis (K) of human primary AML cells from Patient #1. L Quantitative analysis for Fig. 1I. L: live cells; EA: early apoptotic cells; LA: late apoptotic cells. M Quantitative analysis for Fig. 1K. L: live cells; EA: early apoptotic cells; LA: late apoptotic cells. N The effects of ALKBH5 knockdown on global m6A abundance of Kasumi-1 cells and primary cells